NO933321L - NADH og NADPH som legemiddel til behandling av Mobus Alzheimer - Google Patents

NADH og NADPH som legemiddel til behandling av Mobus Alzheimer

Info

Publication number
NO933321L
NO933321L NO933321A NO933321A NO933321L NO 933321 L NO933321 L NO 933321L NO 933321 A NO933321 A NO 933321A NO 933321 A NO933321 A NO 933321A NO 933321 L NO933321 L NO 933321L
Authority
NO
Norway
Prior art keywords
nadh
nadph
alzheimer
treatment
mobus
Prior art date
Application number
NO933321A
Other languages
English (en)
Other versions
NO303482B1 (no
NO933321D0 (no
Inventor
Jorg Birkmayer
Original Assignee
Birkmayer Joerg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birkmayer Joerg filed Critical Birkmayer Joerg
Publication of NO933321D0 publication Critical patent/NO933321D0/no
Publication of NO933321L publication Critical patent/NO933321L/no
Publication of NO303482B1 publication Critical patent/NO303482B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO933321A 1992-09-30 1993-09-17 NADH og NADPH som legemiddel til behandling av Morbus Alzheimer NO303482B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232899A DE4232899C2 (de) 1992-09-30 1992-09-30 Verwendung von NADH und NADPH zur Behandlung von Morbus Alzheimer

Publications (3)

Publication Number Publication Date
NO933321D0 NO933321D0 (no) 1993-09-17
NO933321L true NO933321L (no) 1994-04-05
NO303482B1 NO303482B1 (no) 1998-07-20

Family

ID=6469304

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933321A NO303482B1 (no) 1992-09-30 1993-09-17 NADH og NADPH som legemiddel til behandling av Morbus Alzheimer

Country Status (16)

Country Link
US (1) US5444053A (no)
EP (1) EP0590321B1 (no)
JP (1) JP3384847B2 (no)
CN (1) CN1053341C (no)
AT (1) ATE162076T1 (no)
AU (1) AU664768B2 (no)
CA (1) CA2105912C (no)
DE (2) DE4232899C2 (no)
DK (1) DK0590321T3 (no)
ES (1) ES2111104T3 (no)
GR (1) GR3026120T3 (no)
IL (1) IL106785A (no)
MX (1) MX9306049A (no)
NO (1) NO303482B1 (no)
TW (1) TW231268B (no)
ZA (1) ZA936327B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
CA2369231C (en) * 2000-04-28 2007-04-17 Mizuno Corporation Wrap closure and fit system of footwear
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
DE10254995B4 (de) * 2002-11-26 2005-02-10 Juelich Enzyme Products Gmbh Verfahren zur enzymatischen Reduktion von NAD und NADP
US7034011B2 (en) * 2002-12-03 2006-04-25 Kyowa Hakko Kogyo Co., Ltd. Method of stabilizing reduced nicotinamide adenine dinucleotide or reduced nicotinamide adenine dinucleotide phosphate
US20040126751A1 (en) * 2002-12-27 2004-07-01 Birkmayer Jorg G.D. Method of prolonging the life-span of living cells using NADH, NADPH and ADP-ribose
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US9186350B2 (en) * 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
EP2574339A1 (de) 2011-09-27 2013-04-03 Johannes Huber Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen
CN103340890B (zh) * 2013-06-08 2016-04-27 苏州人本药业有限公司 Nadph作为制备用于防治脑缺血性中风药物方面的应用
CN109562120B (zh) * 2017-08-11 2021-03-19 邦泰生物工程(深圳)有限公司 一种含有nadh和nadph的组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814339A (en) * 1986-02-11 1989-03-21 Advanced Biologics, Inc. Treatment for Alzheimer's disease
DE58905201D1 (de) * 1988-03-01 1993-09-16 Birkmayer Walther Mittel zur behandlung des parkinson-syndroms.
AT397201B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels

Also Published As

Publication number Publication date
US5444053A (en) 1995-08-22
AU664768B2 (en) 1995-11-30
AU4488793A (en) 1994-04-14
JP3384847B2 (ja) 2003-03-10
CA2105912C (en) 2000-11-14
MX9306049A (es) 1994-05-31
NO303482B1 (no) 1998-07-20
NO933321D0 (no) 1993-09-17
DK0590321T3 (da) 1998-09-14
IL106785A0 (en) 1993-12-08
DE4232899A1 (de) 1994-03-31
TW231268B (no) 1994-10-01
IL106785A (en) 1997-09-30
CN1089474A (zh) 1994-07-20
CN1053341C (zh) 2000-06-14
DE59307982D1 (de) 1998-02-19
ZA936327B (en) 1994-03-22
DE4232899C2 (de) 1995-02-23
EP0590321A1 (de) 1994-04-06
ATE162076T1 (de) 1998-01-15
ES2111104T3 (es) 1998-03-01
JPH06192106A (ja) 1994-07-12
CA2105912A1 (en) 1994-03-31
GR3026120T3 (en) 1998-05-29
EP0590321B1 (de) 1998-01-14

Similar Documents

Publication Publication Date Title
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
NO933321L (no) NADH og NADPH som legemiddel til behandling av Mobus Alzheimer
AU1277792A (en) Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
AU3401093A (en) Therapeutic agent for threatened abortion
BR9105183A (pt) Medicamento antidepressivo
BR9203302A (pt) Medicamento contra cancer ou aids
KR100194995B1 (ko) 관상동맥성 심장질환,동맥경화증 및(또는)지방단백질 대사 이상 치료용 약제
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.